TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9036801
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus testosterone (100 mg intramuscularly every 15 days)
Study: 9036801
Drug: Cyclophosphamide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (oral and intravenous) without testosterone
Study: 31780004
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) bundle therapy combined with conventional treatment for sepsis and AGI
Study: 31780004
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received conventional treatment for sepsis and AGI
Study: 29482973
Drug: Standardised intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised intravenous hydration with high dose sodium bicarbonate (1 mL/kg of 8.4% NaHCO3)
Study: 29482973
Drug: Standardised intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised intravenous hydration without sodium bicarbonate (control)
Study: 27095791
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy + depressive relapse active monitoring
Study: 24609624
Drug: Multiple intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravitreal injections of anti-VEGF (more than three injections) in DMR patients
Study: 24609624
Drug: Multiple intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravitreal injections of anti-VEGF (more than three injections) in RVO patients
Study: 23084093
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)
Study: 23084093
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)
Study: 20036117
Drug: CMF (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (oral cyclophosphamide, intravenous methotrexate and 5‐fluorouracil)
Study: 18677165
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical exercise (45 min) at school
Study: 12585827
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (6 million U three times weekly for 48 weeks)
Study: 1928034
Drug: Omnipaque (non-ionic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnipaque (non-ionic, iso-osmolar contrast agent)
Study: 1928034
Drug: Hexabrix (ionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexabrix (ionic contrast agent)
Study: 1928034
Drug: Hypaque (ionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypaque (ionic contrast agent)
Study: 7042068
Drug: Chemotherapy (DTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (DTIC 250 mg/M2 daily x 5 days + actinomycin-D 2 mg/M2 on day 1 every 3-4 weeks)
Study: 7042068
Drug: Chemoimmunotherapy (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (same chemotherapy regimen + C. parvum 2 mg/M2 I.V. daily for 14 days before every third cycle and on days 7 and 14 of each cycle)
Study: 31331579
Drug: Shiatsu therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shiatsu therapy in addition to standard care
Study: 24886541
Drug: Telaprevir monotherapy
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir monotherapy (T arm)
Study: 24886541
Drug: Telaprevir in
Normalized name: Product containing telaprevir in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir in combination with peginterferon/ribavirin (TPR arm)
Study: 24886541
Drug: Telaprevir monotherapy
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir monotherapy (T arm) and TPR arm
Study: 23206461
Drug: Preincisional parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Preincisional parecoxib (40 mg intravenously before skin incision)
Study: 23206461
Drug: Postincisional parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Postincisional parecoxib (40 mg intravenously after skin incision)
Study: 18586901
Drug: Standard photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard photodynamic therapy (sPDT) + 4 mg intravitreal triamcinolone (IVTA)
Study: 18586901
Drug: Reduced fluence
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced fluence photodynamic therapy (rPDT) + 4 mg intravitreal triamcinolone (IVTA)
Study: 12189542
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg m(‐2) i.v. day 1 and gemcitabine 1000 mg m(‐2) i.v. days 1, 8, and 15 of a 28 day cycle for a maximum of six cycles
Study: 12189542
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and gemcitabine treatment
Study: 10365742
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and No Heparin
Study: 7621684
Drug: Levonorgestrel (LNG)‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (LNG)‐releasing subdermal implants (Norplant)
Study: 7621684
Drug: Combined monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined monthly injectable contraceptives (50mg NET‐EN and 5mg estradiol valerate)
Study: 7621684
Drug: Combined low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low‐dose oral pills (triphasic and monophasic)
Study: 2137076
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebulized salbutamol followed by 0.5 mg ipratropium
Study: 2137076
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs administered together followed by nebulized saline
Study: 7003572
Drug: Meptazinol 100
Normalized name: meptazinol 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 100 mg orally
Study: 7003572
Drug: Pentazocine 25
Normalized name: pentazocine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 25 mg orally
Study: 30536589
Drug: GSK3342830 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3342830 (single intravenous doses ranging from 250 to 6000 mg)
Study: 30536589
Drug: GSK3342830 (repeat
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3342830 (repeat intravenous infusions 3 times a day)
Study: 30536589
Drug: GSK3342830 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3342830 (multiple doses)
Study: 30413184
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of varlilumab plus rituximab
Study: 18924648
Drug: TDF/FTC/EFV regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC/EFV regimen (1 pill once a day)
Study: 15804873
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) treatment in combination with buprenorphine (BUP)
Study: 15804873
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) treatment in combination with methadone (Meth)
Study: 8986585
Drug: Earles' balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earles' balanced salt solution supplemented with 15% preovulatory serum (control)
Study: 30500116
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Study: 30500116
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Study: 23090528
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for mild GDM (397 women)
Study: 17156141
Drug: Sulfate supplements
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfate supplements
Study: 17156141
Drug: Sulfate supplements
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfate supplements with senna
Study: 15860487
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 and etoposide 100 mg/m2 (arm A)
Study: 15860487
Drug: Carboplatin AUC=6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin AUC=6 mg/ml min and paclitaxel 225 mg/m2 (arm B)
Study: 10221068
Drug: bisoprolol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol 1.25 mg/day, progressively increased to a maximum of 10 mg/day
Study: 8919833
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg i.v. 1 hour before induction of anaesthesia (Group A)
Study: 8919833
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg i.v. 1 hour before end of surgery (Group B)
Study: 2195929
Drug: Calcitonin 100
Normalized name: salmon calcitonin 100 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin 100 IU every other day plus 1 g of elemental calcium daily
Study: 31909809
Drug: Walnut diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut diet (WD) [57-99 g/d walnuts, 7% SFAs, 16% PUFAs (2.7% ALA), 9% MUFAs]
Study: 19603474
Drug: Additional meat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional meat intake (200 g pork fillet/day)
Study: 17876463
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spraying houses and animal pens, and eliminating infected dogs
Study: 7815703
Drug: Midazolam 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2.5 mg
Study: 6155338
Drug: Intranasal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccination with cold-adapted influenza A/HK/77 (H1N1) CR 35 recombinant virus
Study: 25948064
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg/day for 6 weeks
Study: 23949899
Drug: Mildronate injection
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate injection
Study: 23949899
Drug: Cinepazide injection
Normalized name: cinepazide
DrugBank: Cinepazide (DB12123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinepazide injection (active-control)
Study: 19266829
Drug: Propofol-MCT/LCT premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-MCT/LCT premixed with 20 mg lignocaine (Group B)
Study: 19266829
Drug: Propofol-LCT premixed
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-LCT premixed with 20 mg lignocaine (Group C)
Study: 18664154
Drug: Topical 5-methyl
Normalized name: 5-methyl-8-hydroxyquinoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-methyl aminolevulinate cream applied for 1 hour before red light illumination
Study: 18664154
Drug: Topical 5-methyl
Normalized name: 5-methyl-8-hydroxyquinoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-methyl aminolevulinate cream applied for 3 hours before red light illumination
Study: 18664154
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment sides
Study: 15355485
Drug: Topiramate (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100, 200, or 400 mg/day)
Study: 2422778
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of PPS by intramuscular (I.M.) route (group I)
Study: 2422778
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of PPS by intramuscular (I.M.) route (group II)
Study: 2422778
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of PPS by subcutaneous (S.C.) route (group III)
Study: 2422778
Drug: PPS administration
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPS administration
Study: 11152033
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 0.65-1.0 mg x kg(-1)
Study: 11152033
Drug: Paracetamol 13-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 13-20 mg x kg(-1)
Study: 25027552
Drug: docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel plus cisplatin (20mg/m2/week) with concurrent radiotherapy (54Gy in 30 fractions)
Study: 25027552
Drug: docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel plus 5-fluorouracil with concurrent radiotherapy
Study: 22551208
Drug: Diflunisal, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal, a non-steroidal anti-inflammatory drug (NSAID)
Study: 20206069
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 704 mg orally twice daily (NAC group, n=15)
Study: 20206069
Drug: Aminophylline 250
Normalized name: aminophylline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 250 mg intravenously 30 min before CAG and/or PCI (aminophylline group, n=15)
Study: 17633369
Drug: Panlongqi Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panlongqi Tablet (PLQ) in addition to NSAID and sulfasalazine (SSZ)
Study: 16055815
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (assertive community treatment, psychoeducational multi-family groups, social skills training)
Study: 12170046
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml intravenous saline (Control)
Study: 10525023
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment based on ductal flow pattern assessment (ECHO group)
Study: 10525023
Drug: Conventional indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional indomethacin treatment (protocol group)
Study: 1689934
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg daily
Study: 1689934
Drug: Hydrochlorothiazide +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide + Amiloride 5 mg
Study: 26393373
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy (LTOT) prescribed for 15 hours per day including overnight hours
Study: 9390662
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (5 g PO b.i.d. x 14 days -> 2 g PO b.i.d. x 7 days)
Study: 7970099
Drug: Low-dose OKT3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OKT3 induction therapy (0.5 mg OKT3 twice daily for 10 days)
Study: 7970099
Drug: Low-dose OKT3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OKT3 induction therapy
Study: 2885650
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus pulsed ultrasound given weekly
Study: 2885650
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (paste impregnated bandage and a self‐adhesive elastic bandage)
Study: 21303311
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) at a dose of 200 mcg once daily for eight weeks after RF application
Study: 10678137
Drug: Huperzine-A in
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine-A in capsules (4 capsules of Hup, each contains 50 micrograms)
Study: 10678137
Drug: Huperzine-A in
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine-A in tablets (4 tablets of Hup, each contains 50 micrograms)
Study: 10678137
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 tablets of placebo in capsule group and 4 capsules of placebo in tablet group)
Study: 1503068
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg pyridoxine (PN)-HCl/d supplementation for mothers
Study: 1503068
Drug: 27 mg
Normalized name: aspirin 227 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 mg pyridoxine (PN)-HCl/d supplementation for mothers
Study: 1503068
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg PN-HCl/d supplementation for infants of 2 mg/d supplemented mothers
Study: 6299652
Drug: Griseofulvin 250
Normalized name: griseofulvin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 250 mg daily
Study: 23866179
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg, 75 mg for pre-treated patients)
Study: 15492353
Drug: Risperidone (0.01-0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.01-0.06 mg/kg/day, mean dosage: 0.04 mg/kg/day)
Study: 10094445
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg/kg per 6 h for 4 days)
Study: 10094445
Drug: Control (antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antibiotics alone)
Study: 6548926
Drug: Almax (6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almax (6-8 g/d)
Study: 6548926
Drug: Almax (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almax (4 g/d) with antisecretory drugs (cimetidine or ranitidine)
Study: 6548926
Drug: Almax (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almax (lower doses)
Study: 30005707
Drug: Active acupuncture
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active acupuncture group receiving standardized 30-min real acupuncture treatment for a total of 16 sessions on top of standard routine care.
Study: 18371137
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FeCarb) - maximum 1,000 mg iron per infusion at 1-week intervals until total iron deficit reached
Study: 18371137
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (FeSulf) - 100 mg b.i.d. for 12 weeks
Study: 10584678
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch containing 35 mg nicotine
Study: 1826594
Drug: Teicoplanin at
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin at 6 mg/kg every 12 h for three doses, then 6 mg/kg every 24 h
Study: 1826594
Drug: Vancomycin at
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin at 15 mg/kg every 12 h
Study: 6961760
Drug: Labetalol (667
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (667 mg daily)
Study: 6961760
Drug: Propranolol (129
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (129 mg daily)
Study: 6961760
Drug: Labetalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (400 mg single oral dose)
Study: 28687934
Drug: KGB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: KGB and AG (6 g of fibre from KGB and 3 g of AG)
Study: 19605879
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing plus oral health education
Study: 17238881
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg x kg(‐1)
Study: 11240084
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate immediate release (MSIR)
Study: 799991
Drug: Ibuprofen 1600
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1600 mg/day
Study: 28232973
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral health intervention (spoken)
Study: 26390092
Drug: Control injection
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injection of excipient dosing in the contralateral leg
Study: 23499204
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G sodium and gentamicin
Study: 14681343
Drug: Nanocrystal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nanocrystal budesonide 0.5 mg
Study: 14681343
Drug: Nanocrystal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nanocrystal budesonide 1.0 mg
Study: 14681343
Drug: Pulmicort Respules
Normalized name: Pulmicort Respules
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Respules 0.5 mg
Study: 3513080
Drug: Cimetidine/pyrilamine eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine/pyrilamine eyedrops (combination treatment)
Study: 29848153
Drug: All biologics
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All biologics
Study: 25028536
Drug: Nanocrystal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocrystal formulation of megestrol acetate (625 mg/5 mL) in fasting state
Study: 25028536
Drug: Nanocrystal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocrystal formulation of megestrol acetate (625 mg/5 mL) in fed state